FDA approves new pill to lower cholesterol levels

The FDA has officially approved Lipfendra, a new daily pill designed to help adults manage high LDL cholesterol. Developed by pharmaceutical company Merck, this medication marks the first oral entry into the PCSK9 inhibitor class. Until now, these drugs were only available as injections.

PCSK9 inhibitors work by blocking a specific protein in the body, which allows the liver to remove more bad cholesterol from the bloodstream. High LDL cholesterol is a significant factor in plaque buildup within arteries, which increases the risk of heart attacks and strokes. Given that approximately one in four U.S. adults deals with elevated LDL levels, this treatment offers a new path for patient care.

Medical professionals see the oral format as a major shift. While the injectable versions are effective, many patients have historically been reluctant to use them due to the delivery method or cost concerns. Physicians believe this daily pill will improve patient adherence and provide easier access to a proven treatment class for those at high risk of heart disease.

This approval provides doctors with another tool to manage cardiovascular risk. By offering a convenient alternative to injections, the health sector expects to see broader adoption of this therapy among patients who require additional help reaching their cholesterol goals.